I now have all the content needed to write a comprehensive, textbook-quality comparison. Here is the full response:
Seminomatous vs Non-Seminomatous Germ Cell Tumours (GCTs)
Testicular GCTs account for 95% of all testicular neoplasms. The fundamental clinical distinction is between seminomas and non-seminomatous germ cell tumours (NSGCTs) - this split drives every management decision. Importantly, for a tumour to be classified as a pure seminoma, it must be 100% seminoma histologically; any mixed GCT is managed as an NSGCT. - Harrison's Principles of Internal Medicine 22E, p. 748
All adult GCTs share a pathognomonic genetic marker: isochromosome of the short arm of chromosome 12 (i12p). - Bailey and Love's Short Practice of Surgery 28th Ed, p. 1591
Gross Pathology
Seminoma - a homogeneous, pinkish-cream cut surface that appears to compress neighbouring tissue:
Figure: Seminoma of the testis - Bailey & Love's 28th Ed
1. Classification
| Feature | Seminoma | NSGCT |
|---|
| Proportion of GCTs | ~50% | ~50% |
| Peak age | 4th decade | 3rd decade |
| Histologic rule | Must be 100% seminoma | Any mixed GCT = NSGCT |
| Subtypes | Classic seminoma; spermatocytic seminoma (separate entity, >50 yrs, rarely metastasises) | Embryonal carcinoma, Yolk sac tumour, Choriocarcinoma, Teratoma - often mixed |
Sources: Harrison's 22E, p. 748; Bailey & Love's 28th Ed, p. 1590
2. Histology
Seminoma:
- Oval cells with clear cytoplasm and large, rounded nuclei with prominent acidophilic nucleoli
- Sheets of cells resembling spermatocytes, separated by fine fibrous stroma
- Active lymphocytic infiltration = good host response, better prognosis
- May contain syncytiotrophoblastic cells (which can secrete hCG, but AFP is never elevated)
NSGCT subtypes:
- Embryonal carcinoma - most undifferentiated subtype; highly malignant; can differentiate into other subtypes; may invade cord structures; secretes AFP, hCG, both, or neither
- Yolk sac tumour - loose stroma; secretes AFP; commonest childhood testicular malignancy (rare pure form in adults); part of mixed tumour in adults
- Choriocarcinoma - highly malignant; early haematogenous + lymphatic spread; secretes hCG (often at very high levels); extremely rare as pure form
- Teratoma - derived from ≥2 germinal layers (ectoderm, mesoderm, endoderm); may be mature, immature, or malignant; all can metastasise; importantly, teratomas are chemotherapy resistant and must be treated surgically
Sources: Harrison's 22E, p. 748; Bailey & Love's 28th Ed, p. 1591
3. Tumour Markers
This is one of the most clinically tested differences:
| Marker | Seminoma | NSGCT subtypes |
|---|
| AFP | Never elevated (AFP↑ in a "seminoma" = treat as NSGCT) | Elevated in ~60-70% of NSGCTs; yolk sac (always), embryonal carcinoma (70%), teratoma (38%), choriocarcinoma (0%) |
| hCG (β-hCG) | Elevated in only ~7% (via syncytiotrophoblast cells) | Elevated variably: choriocarcinoma (100%), embryonal (60%), teratoma (25%) |
| LDH | Elevated in high tumour burden | Less specific; elevated in recurrent NSGCT |
AFP is never secreted by seminoma. A seminoma patient with elevated AFP must be managed as NSGCT. - Harrison's 22E, p. 749; Smith & Tanagho's General Urology 19th Ed, p. 394
4. Pattern of Spread
- Both initially spread via lymphatics to para-aortic nodes (lymphatic drainage of the testes follows the gonadal vessels, not inguinal nodes - inguinal nodes are involved only if scrotal skin is breached)
- Seminoma - predominantly lymphatic spread; haematogenous spread is uncommon
- Choriocarcinoma (NSGCT) - early haematogenous spread (lungs most common distant site); most aggressive of all subtypes
- Subsequent spread: retrocrural → mediastinal → supraclavicular nodes, then haematogenous to lungs, liver, bone, brain
5. Sensitivity to Treatment
| Seminoma | NSGCT |
|---|
| Radiotherapy | Exquisitely sensitive | Relatively resistant |
| Chemotherapy (platinum-based) | Highly sensitive | All subtypes sensitive except teratoma |
| Teratoma specifically | N/A | Chemotherapy resistant - must be resected |
6. Staging
Both use TNM staging (AJCC):
- Stage I - confined to testis
- Stage II - retroperitoneal lymph node involvement
- Stage III - beyond retroperitoneum and/or distant metastases
The International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification differs between seminoma and NSGCT:
| Risk | Seminoma | NSGCT |
|---|
| Good | Any primary site; normal AFP, any hCG, any LDH; no non-pulmonary visceral mets | Testicular/retroperitoneal primary; no non-pulmonary visceral mets; markers at S1 level |
| Intermediate | Any primary; nonpulmonary visceral mets present | Testicular/retroperitoneal primary; nonpulmonary visceral mets absent; intermediate marker level |
| Poor | No poor-risk category for seminoma | Mediastinal primary OR nonpulmonary visceral mets OR high markers |
Importantly, seminoma has no "poor risk" IGCCCG category. - Harrison's 22E, p. 749
7. Stage-Based Management
Stage I Seminoma:
- ~70% of seminomas present at Stage I
- ~15% have occult retroperitoneal micrometastases
- Options: active surveillance (preferred), adjuvant paraaortic radiotherapy, or carboplatin monotherapy (1-2 cycles)
- Active surveillance is the standard as the vast majority are cured by orchiectomy alone
Stage I NSGCT:
- Options: active surveillance, nerve-sparing retroperitoneal lymph node dissection (RPLND), or adjuvant BEP chemotherapy x1 cycle
- RPLND is both diagnostic and therapeutic
Advanced disease (Stage II/III) - both types:
- BEP chemotherapy (bleomycin, etoposide, cisplatin) is the backbone
- Post-chemotherapy residual masses in NSGCT require surgical resection (teratoma is chemo-resistant; viable cancer may be present)
- Post-chemotherapy residual masses in seminoma: PET scan is used (FDG-avid = residual disease; PET-negative masses can be observed as they may be necrosis/fibrosis)
Source: Harrison's Principles of Internal Medicine 22E, pp. 749-751; Bailey & Love's 28th Ed
Quick Reference Summary
| Feature | Seminoma | NSGCT |
|---|
| Age peak | 4th decade | 3rd decade |
| AFP | Never elevated | Often elevated |
| hCG | Rarely (~7%) | Variably elevated |
| Radiotherapy | Sensitive | Resistant |
| Chemo (platinum) | Sensitive | Sensitive (except teratoma) |
| Teratoma | N/A | Chemo-resistant; needs surgery |
| IGCCCG poor risk | Does NOT exist | Exists |
| Spread | Mainly lymphatic | Lymphatic + early haematogenous (especially choriocarcinoma) |
| Prognosis | Generally excellent (~95% cure) | Excellent if good-risk (~95% cure), worse if poor-risk |
| Post-chemo residual | PET to assess; observe if negative | Resect (may be teratoma or viable cancer) |
The ~95% overall cure rate makes testicular GCT a "model for a curable neoplasm" - one of oncology's landmark achievements. - Harrison's Principles of Internal Medicine 22E, p. 748